Clinical trials: Neoplasm Recurrence
Recurrent Ovarian Epithelial Cancer
Oxaliplatin and Topotecan in Advance Ovarian Cancer
This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
- Trial name
- NCT00313612
- Testing
- oxaliplatin, topotecan
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Disc Herniation, Disk Herniated Lumbar
Safety And Performance Of Disc Care To Prevent Lumbar Disc Herniation Recurrence
The goal of this clinical investigation is to learn about DISC Care, an Hernia Blocking System, in patients who have undergone lumbar disc hernia surgery.
- Trial name
- ACE-2 (NCT06023719)
- Testing
- DISC Care
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- NEOS Surgery
Metastatic Colorectal Cancer
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
- Trial name
- NCT00378066
- Testing
- Bevacizumab
- Where
- 6 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Asan Medical Center
Atrial Fibrillation (AF)
Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation
This study aims to investigate the efficacy and safety of intravenous combined with oral amiodarone in preventing atrial fibrillation (AF) recurrence after catheter ablation in patients with persistent atrial fibrillation.
- Trial name
- NCT06742866
- Testing
- Amiodarone Injection, Sodium Chloride Injection 0.9%
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Shanghai Chest Hospital
Melanoma (Skin)
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Trial name
- NCT00798629
- Testing
- Autologous dendritic cell-adenovirus CCL21 vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Small Cell Lung Carcinoma
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
This is a prospective, open-label, uncontrolled and multicenter phase I/II study of PM01183 in combination with pembrolizumab in patients with relapsed small cell lung cancer (SCLC).
- Trial name
- LUPER (NCT04358237)
- Testing
- Lurbinectedin, Pembrolizumab
- Where
- 5 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Antonio Calles Blanco
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as FR901228 (depsipeptide), work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00087295
- Testing
- Depsipeptide
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Adult Glioblastoma, Depression
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
This clinical trial is studying magnetic resonance spectroscopy imaging in predicting response in patients to vorinostat and temozolomide in patients with recurrent, progressive, or newly diagnosed glioblastoma.
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Trial name
- NCT01342757
- Testing
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Diagnosed or Relapsed/Refractory Sarcomas
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme.
- Trial name
- NCT04621201
- Testing
- observation and biopsy
- Where
- 10 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Small-cell Lung Cancer
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.
- Trial name
- NCT03613753
- Testing
- irinotecan plus lobaplatin, irinotecan
- Where
- China
- Volunteers
- 72 people
- Sponsor
- ShengFa Su
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back…
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Trial name
- NCT04169737
- Testing
- Acalabrutinib, Obinutuzumab, Venetoclax
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer
Effect of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer. The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are…
- Trial name
- NCT01530295
- Testing
- DOCETAXEL
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Hanjong Ahn
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
- Trial name
- NCT01466257
- Testing
- cetuximab, cisplatin, DNA analysis
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003281
- Testing
- paclitaxel, topotecan hydrochloride, radiation therapy
- Where
- 19 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Endometrial Cancer
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
The main purpose of this study is to see if adding the experimental medication, axitinib, to usual treatment with pembrolizumab will work better than pembrolizumab alone.
- Trial name
- NCT04197219
- Testing
- Pembrolizumab, Axitinib
- Sponsor
- Case Comprehensive Cancer Center
Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01045928
- Testing
- lenalidomide, rituximab, polymerase chain reaction
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myelogenous Leukemia
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a daily times 3 schedule in…
- Trial name
- NCT00486265
- Testing
- AZD4877
- Where
- 4 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
The purpose of this study is to evaluate the activity of RO4929097 in renal cell carcinoma patients that have failed therapy with VEGF/VEGFR directed agents.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT01141569
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 4 sites in Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.